The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality
J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543. Online ahead of print.
Scott A McDonald1, Stephen T Barclay2, Hamish A Innes1, Andrew Fraser3, Peter C Hayes4, Andrew Bathgate4, John F Dillon5, April Went6, David J Goldberg1, Sharon J Hutchinson1
Author information
1School of Health and Life Sciences, Glasgow Caledonian University and Health Protection Scotland, Glasgow, UK.
2Glasgow Royal Infirmary, Glasgow, UK.
3Aberdeen Royal Infirmary, Aberdeen, and Queen Elizabeth University Hospital, Glasgow, UK.
4Royal Infirmary of Edinburgh, Edinburgh, UK.
5School of Medicine, University of Dundee, Dundee, UK.
6Health Protection Scotland, Glasgow, UK.
Abstract
Interferon-free DAA therapies have recently been licensed for patients infected with hepatitis C virus (HCV) who have decompensated cirrhosis (DC). Our aim was to describe factors associated with uptake of IFN-free DAAs in DC patients and to compare mortality risk and hospital admission rates between pre-DAA and DAA eras. This observational study used record-linkage between Scotland's HCV Clinical Database and national inpatient hospitalisation and mortality registers. For the DAA uptake analysis, the study population (n=297) was restricted to patients alive on 1 November 2014, and Cox regression was used to estimate uptake associated with various covariates. For the Cox regression of mortality comparing pre-DAA and DAA eras, the study population (n=624) comprised those diagnosed with DC in 2005-2018; follow-up was censored at two years. DAA uptake was 63% overall, and was significantly higher for treatment-experienced patients (adjusted hazard ratio (aHR)=1.64, 95% CI:1.14-2.34), genotype 1 vs. other genotypes (aHR=1.55. 95% CI:1.15-2.10), and lower for persons diagnosed with DC pre-2014 (0.47, 95% CI:0.33-0.68) and in Greater Glasgow (0.64, 95% CI:0.47-0.88). The intention-to-treat SVR rate was 89% (95% CI:83-93%). All-cause and liver-related mortality risk were significantly reduced among patients diagnosed with DC in the DAA era (Nov 2014-Dec 2018) compared with the pre-DAA era (2005-Oct 2014) (aHRs of 0.68, 95% CI:0.49-0.93; 0.69, 95% CI:0.50-0.95, respectively); in contrast, hospital admission rates were higher in the DAA era (aRR=1.14, 95% CI:1.04-1.26). The majority of HCV-infected DC patients engaged with specialist services can be treated with IFN-free DAAs. Improved survival among patients diagnosed with DC in the DAA era supports the beneficial impact of IFN-free therapies among those with advanced liver disease.